These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 8198970)
1. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970 [TBL] [Abstract][Full Text] [Related]
2. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188 [TBL] [Abstract][Full Text] [Related]
4. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347 [TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708 [TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Nasir L; Rutteman GR; Reid SW; Schulze C; Argyle DJ Cancer Lett; 2001 Dec; 174(1):83-9. PubMed ID: 11675155 [TBL] [Abstract][Full Text] [Related]
7. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040 [TBL] [Abstract][Full Text] [Related]
8. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877 [TBL] [Abstract][Full Text] [Related]
9. p53 mutations and overexpression in locally advanced breast cancers. Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984 [TBL] [Abstract][Full Text] [Related]
10. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343 [TBL] [Abstract][Full Text] [Related]
11. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802 [TBL] [Abstract][Full Text] [Related]
12. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661 [TBL] [Abstract][Full Text] [Related]
13. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours. Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619 [TBL] [Abstract][Full Text] [Related]
14. Altered patterns of MDM2 and TP53 expression in human bladder cancer. Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890 [TBL] [Abstract][Full Text] [Related]
15. p53 alterations in uterine leiomyosarcomas versus leiomyomas. de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247 [TBL] [Abstract][Full Text] [Related]
16. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591 [TBL] [Abstract][Full Text] [Related]
17. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888 [TBL] [Abstract][Full Text] [Related]
18. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665 [TBL] [Abstract][Full Text] [Related]
19. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. Jeffers MD; Farquharson MA; Richmond JA; McNicol AM J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782 [TBL] [Abstract][Full Text] [Related]
20. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]